Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections; Pneumonia
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 30 Aug 2017 Results published in the Vaccine
- 29 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.